Table 2.
Current list of FDA-approved PD-L1 inhibitors along with indications, dosages, and bioassay for the PD-L1 expression
| PD-L1 inhibitors | Indications | Dosages and schedules | PD-L1 bioassays | PD-L1 cutoff | References |
|---|---|---|---|---|---|
| Atezolizumab (MPDL3280A) | NSCLC | 1200 mg over 60 min q3 weeks | Roche Ventana SP142 | ≥ 50% TC or ≥ 10% IC | [42] |
| UC | ≥ 5% IC | [38] | |||
| ES-SCLC | N/A | [44] | |||
| TNBC | 840 mg q1 and 15 | ≥ 1% IC | [45] | ||
| Durvalumab (MEDI4736) | UC | 10 mg/kg over 60 min q2 weeks | Roche Ventana SP263 | ≥ 25% TC or ≥ 25% IC | [59] |
| Unresectable stage III NSCLC | ≥ 1% TC | [60] | |||
| Avelumab (MSB0010718C) | MCC | 10 mg/kg over 60 min q2 weeks | N/A | N/A | [69] |
| RCC | [79] |
NSCLC non-small cell lung cancer, UC urothelial cancer, MCC Merkel cell carcinoma, TNBC triple-negative breast cancer, RCC renal cell carcinoma, ESSCLC extensive-stage small cell carcinoma, % IC percentage PD-L1 expressing tumor-infiltrating immune cells of any intensity of the tumor area, % TC percentage of PD-L1 expressing tumor cells of any intensity